Anterior Femoral and Adductor Canal Nerve Blocks in Peds Knees
Launched by HOSPITAL FOR SPECIAL SURGERY, NEW YORK · Sep 6, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different ways to provide pain relief for children and teenagers aged 8 to 18 who are having surgery on their knees, specifically for anterior cruciate ligament (ACL) or medial patellofemoral ligament (MPFL) reconstruction. The researchers want to find out which method—anterior femoral cutaneous nerve block (AFCN) or adductor canal block (ACB)—is more effective. They will measure how well the patients recover, how much pain medication they need after surgery, and how they feel about their pain management.
To participate in this study, patients must be between 8 and 18 years old and weigh at least 40 kilograms. They cannot be having a revision surgery (a surgery to fix a previous one), have surgery on both knees at the same time, or have any serious pre-existing conditions that could affect the study. If they join, participants will be randomly assigned to receive either the AFCN or ACB along with regular pain management. They will keep a diary to track their pain and medication use and will also answer follow-up questions after their surgery. This trial is currently recruiting participants, and your doctor can provide more information if you think your child might be eligible.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 8-18 years old at the time of surgery
- • Patients 40kg and above
- • ACL reconstruction of MPFL reconstruction surgery with participating surgeons
- Exclusion Criteria:
- • revision surgery
- • bilateral surgery
- • general anesthesia
- • contraindications to any part of the study protocol
- • relevant pre-existing neurological deficit
- • chronic pain
About Hospital For Special Surgery, New York
The Hospital for Special Surgery (HSS) in New York is a world-renowned institution specializing in orthopedic surgery, rheumatology, and rehabilitation. Recognized for its commitment to advancing medical research and improving patient outcomes, HSS serves as a leading clinical trial sponsor, facilitating innovative studies that explore cutting-edge treatments and therapies. With a team of expert clinicians and researchers, HSS aims to enhance clinical practices through rigorous scientific inquiry, ultimately contributing to the advancement of musculoskeletal health and patient care on a global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Kathryn DelPizzo, MD
Principal Investigator
Hospital for Special Surgery, New York
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported